Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Ankylosing Spondylitis Market from 2024 to 2025?

The market for ankylosing spondylitis has experienced robust growth in the past few years. Its size is projected to surge from $5.9 billion in 2024 to $6.36 billion in 2025, marking a compound annual growth rate (CAGR) of 7.8%. The historical growth of this market owes to factors such as the discovery of hla-b27, advancements in biologic treatments, the advent of pain management techniques, heightened patient advocacy and awareness, as well as the use of NSAIDS and disease-modifying drugs.

What Is the Projected Market Size of the Ankylosing Spondylitis Market?

In the upcoming years, the market size of ankylosing spondylitis is projected to enjoy robust expansion. It’s forecasted to escalate to $8.71 billion by 2029 with a compound annual growth rate (CAGR) of 8.2%. The significant growth predicted for this period can be linked to factors such as the emergence of personalized medicine, the creation of novel biologics, early intervention and screenings, management of lifestyle and diet, and the implementation of telemedicine and remote monitoring. Notable trends within this forecast period encompass the availability of biosimilars, the focus on targeted pain therapies, the emphasis on patient reported outcomes (PROs), the existence of community support programs, and exploration into regenerative medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Who are the Major Competitors in the Ankylosing Spondylitis Market Outlook?

Major companies operating in the ankylosing spondylitis market include Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

What Is Fueling Growth in the Ankylosing Spondylitis Market?

The projected growth of the ankylosing spondylitis market is anticipated to be fuelled by the rise in the elderly population. The term “geriatric population” denotes an uptick in the number of older individuals resulting from shifts in population age structure. This demographic transition has escalated both the count and the ratio of individuals aged 60 and above. Therapies and medications for ankylosing spondylitis provide pain management and enhance mobility in geriatric patients suffering from the condition. For instance, future projections from the United Nations Department of Economic and Social Affairs (UN DESA), an agency of the UN Secretariat headquartered in the US, in January 2023, estimated that the global population of people aged 65 and above is set to double. The numbers are expected to swell from 761 million in 2021 to about 1.6 billion by 2050. Consequently, the burgeoning geriatric population is serving as a catalyst for the expansion of the ankylosing spondylitis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11962&type=smp

Which Ankylosing Spondylitis Market Segments Are Growing the Fastest?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

Which Industry Trends Are Shaping the Future of the Ankylosing Spondylitis Market?

The evolution of therapeutic strategies is an emerging trend gaining traction in the ankylosing spondylitis market. Key players in the ankylosing spondylitis sector are developing novel treatments to maintain their market presence. For instance, in April 2022, AbbVie Inc., a biopharmaceutical firm based in the United States, announced the U.S. Food and Drug Administration’s (FDA) approval of RINVOQ for treating adults suffering from active ankylosing spondylitis (AS). This furnishes a fresh oral treatment method for patients unresponsive to TNF blockers, indicating remarkable enhancement in disease indications such as backache and physical functioning. The fast effectiveness and safety credentials from clinical trials make it a significant advancement in managing this ongoing inflammatory ailment, broadening the therapeutic options available to patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Countries Are Leading the Ankylosing Spondylitis Market?

North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11962

This Report Delivers Insight On:

1. How big is the ankylosing spondylitis market, and how is it changing globally?

2. Who are the major companies in the ankylosing spondylitis market, and how are they performing?

3. What are the key opportunities and risks in the ankylosing spondylitis market right now?

4. Which products or customer segments are growing the most in the ankylosing spondylitis market?

5. What factors are helping or slowing down the growth of the ankylosing spondylitis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model